Method for non surgical repair of vertebral compression fractures 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2015187994 A1 2015-12-10 [WO2015187994] / 2015-12-10
申请号/申请日
2015WO-US34275 / 2015-06-04
发明人
GAZIT DAN;SCHWARZ EDWARD M;BAE HYUN;PELLED GADI;GAZIT ZULMA;SHEYN DMITRIY;TAWACKOLI WAFA;
申请人
CEDARS SINAI MEDICAL CENTER;
主分类号
IPC分类号
A01N-063/00A61K-038/00A61P-019/10
摘要
(WO2015187994) Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions.  Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture.  The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair.  The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH + MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2014US-62007793 2014-06-04 2015US-62129720 2015-03-06
主权利要求
(WO2015187994) THE CLAIMS 1. A method for modulating bone texture, comprising: selecting a subject; and administering a quantity of mesenchymal stem cells (MSCs) and a quantity of parathyroid hormone (PTH), wherein administration of both MSCs and PTH modulates bone texture in the subject. 2. The method of claim 1, wherein the administration of MSCs and PTH is simultaneous. 3. The method of claim 1, comprising further administration of PTH. 4. The method of claim 1, wherein the administration of MSCs and PTH is sequential. 5. The method of claim 1, wherein the administration of MSCs comprises intravenous injection into the subject. 6. The method of claim 1, wherein the administration of PTH comprises subcutaneous injection into the subject. 7. The method of claim 1, wherein the quantity of MSCs comprises at least lxlO6, 2xl06, 3xl06, 4xl06or 5xl06cells. 8. The method of claim 1, wherein the quantity of PTH comprises 0.1 to 1, 1-10, 10-20, 20- 30, 30-40, or at least 40 ug/kg. 9. The method of claim 1, wherein modulating bone texture comprises a change in trabecular thickness and/or bone density. 10. The method of claim 9, wherein the change in trabecular thickness and/or bone density is in spinal vertebrae. 11. The method of claim 10, wherein the spinal vertebrae are lumbar spinal vertebrae. 12. The method of claim 1, wherein the wherein modulating bone texture comprises a change in trabecular thickness and/or bone density in one or more ribs. 13. The method of claim 1, wherein the MSCs express a heterologous protein. 14. The method of claim 13, wherein the heterologous protein comprises bone morphogenic proteins (BMPs). 15. The method of claim 14, wherein the BMPs comprise BMP-2, BMP-6, or both. 16. A method for increasing mesenchymal stem cell homing, comprising: selecting a subject; and administering a quantity of mesenchymal stem cells (MSCs) and a quantity of parathyroid hormone (PTH), wherein administration of both MSCs and PTH increases MSC homing in the subject. 17. The method of claim 16, wherein the MSC homing occurs in spinal vertebrae. 18. The method of claim 17, wherein the spinal vertebrae are lumbar spinal vertebrae. 19. The method of claim 16, wherein MSC homing occurs in one or more ribs. 20. The method of claim 16, wherein the administration of a quantity of MSCs comprises intravenous injection of at least lxl 06cells into the subject, and administration of a quantity of PTH comprises subcutaneous injection at least 0.1 ug/kg of PTH injection into the subject. 21. The method of claim 20, comprising further daily administration of at least 0.1 ug/kg of PTH for at least 1 week, 2 weeks, or 3 weeks. 22. The method of claim 16, wherein the MSCs express a heterologous protein. 23. The method of claim 22, wherein the heterologous protein comprises bone morphogenic proteins (BMPs). 24. The method of claim 23, wherein the BMPs comprise BMP-2, BMP-6, or both. 25. The method of claim 16, wherein the MSCs are human and are derived from bone marrow or adipose tissue. 26. The method of claim 16, wherein the MSCs express one or more of CD90+, CD44+, CD29+, CD73+, and CD105+. 27. The method of claim 16, wherein the MSCs express CXCR4+. 28. A method of treating osteoporotic related conditions, comprising: selecting a human subject; administering a quantity of at least lxl 06human mesenchymal stem cells (MSCs) and a quantity of at least 0.1 ug/kg of parathyroid hormone (PTH); and further daily administration of at least 0.1 ug/kg of PTH for at least 1 week, wherein administration of human MSCs comprises intravenous injection, administration of PTH comprises subcutaneous injection, wherein administration of both MSCs and PTH treated the osteoporotic related condition. 29. The method of claim 28, wherein the quantity of PTH comprises 1-5 ug/kg. 30. The method of claim 28, wherein the MSCs are derived from bone marrow or adipose tissue and express CD90+, CD44+, CD29+, CD73+, and CD105+. 31. The method of claim 28, wherein osteoporotic related condition comprises vertebral compression fractures.
法律状态
(WO2015187994) LEGAL DETAILS FOR WO2015187994  Actual or expected expiration date=2018-09-06    Legal state=ALIVE    Status=PENDING     Event publication date=2015-06-04  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2015034275  Application date=2015-06-04  Standardized application number=2015WO-US34275     Event publication date=2015-12-10  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2015187994  Publication stage Code=A1  Publication date=2015-12-10  Standardized publication number=WO2015187994  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2016-12-05    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2016-12-05  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP3151847  Actual or expected expiration date=2035-06-04    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP15803714  Application date in the designated or member state=2015-06-04   Application number in the designated or member state=2015EP-0803714 Corresponding cc:  Designated or member state=EP Corresponding pat: EP3151847  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-04-12   Publication number in the designated or member state=EP3151847    Event publication date=2016-01-20  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2016-11-30  Event code=WO/REEP  Event indicator=Pos  Event type=Entry into national phase  Request for entry into the European phase Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE JP2017520537  Actual or expected expiration date=2035-06-04    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2016571044  Application date in the designated or member state=2015-06-04   Application number in the designated or member state=2016JP-0571044 Corresponding cc:  Designated or member state=JP Corresponding pat: JP2017520537  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-07-27   Publication number in the designated or member state=JP2017520537    Event publication date=2016-12-02  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE US2017119823  Actual or expected expiration date=2035-06-04    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=US Corresponding appl: US15315704  Application date in the designated or member state=2015-06-04   Application number in the designated or member state=2015US-15315704 Corresponding cc:  Designated or member state=US Corresponding pat: US2017119823  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-05-04   Publication number in the designated or member state=US20170119823    Event publication date=2016-12-01  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=US
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部